Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cytek Biosciences, Inc.

NASDAQ: CTKB · Industrial Applications and Services · 2 alerts · CIK 1831915

Share price
$5.63Close, Nov 16
Market cap
$736M
Shares outstanding
130.78MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cytek Biosciences, Inc. filings on SEC EDGAR ↗

5:03 PM ET 10-Q
Financial Results

Cytek Biosciences Q3 2026 Results: Net Loss of $6.1M, Loss Widens

Cytek Biosciences reported a net loss of $37.1 million for the nine months ended September 30, 2026, compared to a $22.5 million loss in the prior year period, despite a 4% increase in total revenue to $145.5 million. The increased loss was primarily driven by higher general and administrative expenses and a significant decrease in other income compared to 2025.

Key figure
Net loss $6.1M
4:17 PM ET 8-K
Financial Results

Cytek Biosciences Financial Results

Cytek Biosciences reported Q3 2026 revenue of $53.2 million, a 2% increase year-over-year, driven by 12% growth in the U.S. market and strong demand for high-end instruments. The company achieved a GAAP gross margin of 59% and narrowed its full-year 2026 revenue guidance to a range of $208 million to $211 million.

Term
Q3 2026

“We delivered another solid third quarter, with growth led by the U.S., where revenue grew 12%, and double-digit growth in our service business. Demand for our high-end instruments remained strong, with high-end Full Spectrum Profiling instrument revenue up 11% and Aurora Evo placements nearly doubling year over year. We also expanded gross margin by nearly 600 basis points. Looking ahead, we are reiterating the midpoint of our full-year revenue guidance and expect a strong finish to the year. We are well positioned to keep gaining market share, with our new product launches continuing to strengthen our technology leadership.”

Wenbin Jiang, CEO of Cytek Biosciences

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.